We find ourselves in the middle of a global pandemic that is causing a great deal of uncertainty from international governments to individual families. With that in mind, I want Symcel’s position to be clear throughout and we will be posting regular...
COVID-19 is forcing everyone to reconsider how they work. At Symcel, while we place a lot of value on personal interactions, we also have strong digital workflows that allow us to do our jobs remotely. These workflows have prepared us for the...
The first publication from Symcel’s European H2020 project was published at the end of January. The project named BADGER (Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time) focuses on clinical validation for new...
The Bjarnsholt lab at the Costerton Biofilm Center finalized the purchase of a calScreener™ as part of a Novo Nordisk Fonden Tandem grant to study atopic dermatitis.
Symcel’s CEO & CSO during their visit at Professor Müller’s lab. Internationally leading group at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has acquired a calScreener to be used in their screening of novel antimicrobials. ...
Our Production and Application Engineer, Sandra Månsson, with the first calScreener she built.
Why is antibiotic resistance a global threat? The challenges of antibiotic resistance, the current situation that marks it as a WHO priority and the potential of customized therapy are some of the issues that the CEO of Symcel, Dr Jesper Ericsson,...
Our colleague Dr. Karin Gillner recently had a feature article on brown fat treatment research published in Journal for Clinical Studies.
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Internationally renowned clinical microbiologist takes academic lead in Horizon 2020 funded validation of game-changing method for multiple antibiotic resistance evaluation 11 April 2018: Symcel – the company behind the revolutionary cell-based...